FHTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Foghorn Therapeutics Inc (FHTX) is not a strong buy at this moment for a beginner, long-term investor. While the stock shows potential with its clinical pipeline and partnerships, the lack of immediate catalysts, weak financial performance, and neutral trading sentiment suggest holding off on investing right now. The investor may consider re-evaluating closer to the Phase 1 data release in 2026.
The technical indicators are mixed. The MACD is positive and expanding, suggesting bullish momentum. The RSI is neutral at 56.818, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the price is currently trading near resistance levels (R1: 5.899), which could limit short-term upside.
Partnership with Eli Lilly for FHD-909, a promising clinical asset.
Appointment of an experienced CFO, Ryan Maynard, who has a strong track record in raising capital.
Analysts maintain a Buy rating with price targets significantly higher than the current price, indicating long-term potential.
Weak financial performance in the latest quarter, with declining net income (-17.12% YoY) and EPS (-19.35% YoY).
No immediate catalysts until 2026 for Phase 1 data readout.
Neutral sentiment from hedge funds and insiders, with no significant trading activity.
In Q3 2025, revenue increased by 4.42% YoY to $8.15M, but net income dropped by 17.12% YoY to -$15.85M. EPS also fell by 19.35% YoY to -0.25. While gross margin remained strong at 100%, the overall financial performance indicates challenges in profitability.
Analysts are positive on FHTX with Buy ratings and price targets ranging from $11 to $12, significantly above the current price of $5.77. They highlight the potential of FHD-909, with a favorable long-term outlook into 2026 and beyond. However, the lack of near-term catalysts tempers enthusiasm.
